1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Fruquintinib Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 1 mg capsule
  • 1.3.3 5 mg capsule
• 1.4 Market Analysis by Sales Channels
  • 1.4.1 Overview: Global Fruquintinib Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
  • 1.4.2 Hospital
  • 1.4.3 Retail
  • 1.4.4 Online
• 1.5 Market Analysis by Application
  • 1.5.1 Overview: Global Fruquintinib Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.5.2 Metastatic Colorectal Cancer (mCRC)
  • 1.5.3 Inhibit Tumor Angiogenesis
  • 1.5.4 Others
• 1.6 Global Fruquintinib Market Size & Forecast
  • 1.6.1 Global Fruquintinib Consumption Value (2021 & 2025 & 2032)
  • 1.6.2 Global Fruquintinib Sales Quantity (2021-2032)
  • 1.6.3 Global Fruquintinib Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 Hutchison China MediTech Limited
  • 2.1.1 Hutchison China MediTech Limited Details
  • 2.1.2 Hutchison China MediTech Limited Major Business
  • 2.1.3 Hutchison China MediTech Limited Fruquintinib Product and Services
  • 2.1.4 Hutchison China MediTech Limited Fruquintinib Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 Hutchison China MediTech Limited Recent Developments/Updates
• 2.2 Takeda Pharmaceutical Company Limited
  • 2.2.1 Takeda Pharmaceutical Company Limited Details
  • 2.2.2 Takeda Pharmaceutical Company Limited Major Business
  • 2.2.3 Takeda Pharmaceutical Company Limited Fruquintinib Product and Services
  • 2.2.4 Takeda Pharmaceutical Company Limited Fruquintinib Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.2.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
• 2.3 Sichuan Qingmu Pharmaceutical
  • 2.3.1 Sichuan Qingmu Pharmaceutical Details
  • 2.3.2 Sichuan Qingmu Pharmaceutical Major Business
  • 2.3.3 Sichuan Qingmu Pharmaceutical Fruquintinib Product and Services
  • 2.3.4 Sichuan Qingmu Pharmaceutical Fruquintinib Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.3.5 Sichuan Qingmu Pharmaceutical Recent Developments/Updates
• 2.4 Shanghai Boyi Chemical
  • 2.4.1 Shanghai Boyi Chemical Details
  • 2.4.2 Shanghai Boyi Chemical Major Business
  • 2.4.3 Shanghai Boyi Chemical Fruquintinib Product and Services
  • 2.4.4 Shanghai Boyi Chemical Fruquintinib Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.4.5 Shanghai Boyi Chemical Recent Developments/Updates

3 Competitive Environment: Fruquintinib by Manufacturer

• 3.1 Global Fruquintinib Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Fruquintinib Revenue by Manufacturer (2021-2026)
• 3.3 Global Fruquintinib Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Fruquintinib by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Fruquintinib Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Fruquintinib Manufacturer Market Share in 2025
• 3.5 Fruquintinib Market: Overall Company Footprint Analysis
  • 3.5.1 Fruquintinib Market: Region Footprint
  • 3.5.2 Fruquintinib Market: Company Product Type Footprint
  • 3.5.3 Fruquintinib Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Fruquintinib Market Size by Region
  • 4.1.1 Global Fruquintinib Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Fruquintinib Consumption Value by Region (2021-2032)
  • 4.1.3 Global Fruquintinib Average Price by Region (2021-2032)
• 4.2 North America Fruquintinib Consumption Value (2021-2032)
• 4.3 Europe Fruquintinib Consumption Value (2021-2032)
• 4.4 Asia-Pacific Fruquintinib Consumption Value (2021-2032)
• 4.5 South America Fruquintinib Consumption Value (2021-2032)
• 4.6 Middle East & Africa Fruquintinib Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Fruquintinib Sales Quantity by Type (2021-2032)
• 5.2 Global Fruquintinib Consumption Value by Type (2021-2032)
• 5.3 Global Fruquintinib Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Fruquintinib Sales Quantity by Application (2021-2032)
• 6.2 Global Fruquintinib Consumption Value by Application (2021-2032)
• 6.3 Global Fruquintinib Average Price by Application (2021-2032)

7 North America

• 7.1 North America Fruquintinib Sales Quantity by Type (2021-2032)
• 7.2 North America Fruquintinib Sales Quantity by Application (2021-2032)
• 7.3 North America Fruquintinib Market Size by Country
  • 7.3.1 North America Fruquintinib Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Fruquintinib Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Fruquintinib Sales Quantity by Type (2021-2032)
• 8.2 Europe Fruquintinib Sales Quantity by Application (2021-2032)
• 8.3 Europe Fruquintinib Market Size by Country
  • 8.3.1 Europe Fruquintinib Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Fruquintinib Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Fruquintinib Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Fruquintinib Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Fruquintinib Market Size by Region
  • 9.3.1 Asia-Pacific Fruquintinib Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Fruquintinib Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Fruquintinib Sales Quantity by Type (2021-2032)
• 10.2 South America Fruquintinib Sales Quantity by Application (2021-2032)
• 10.3 South America Fruquintinib Market Size by Country
  • 10.3.1 South America Fruquintinib Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Fruquintinib Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Fruquintinib Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Fruquintinib Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Fruquintinib Market Size by Country
  • 11.3.1 Middle East & Africa Fruquintinib Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Fruquintinib Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Fruquintinib Market Drivers
• 12.2 Fruquintinib Market Restraints
• 12.3 Fruquintinib Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Fruquintinib and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Fruquintinib
• 13.3 Fruquintinib Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Fruquintinib Typical Distributors
• 14.3 Fruquintinib Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Fruquintinib market size was valued at US$ 479 million in 2025 and is forecast to a readjusted size of US$ 1379 million by 2032 with a CAGR of 14.6% during review period.
In 2025, global production of fruquintinib reached approximately 810,000 units.Fruquintinib is an oral small-molecule highly selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, primarily used for the treatment of various solid tumors, with demonstrated efficacy particularly in metastatic colorectal cancer. It exerts its anti-tumor effects by selectively inhibiting VEGFR-1, VEGFR-2, and VEGFR-3 signaling pathways, thereby blocking angiogenesis and suppressing tumor growth and metastasis. Fruquintinib is characterized by high target selectivity, convenient oral administration, and good tolerability, making it clinically valuable in the treatment of advanced cancers, especially in later-line therapy settings.
Fruquintinib, as a highly selective VEGFR tyrosine kinase inhibitor, holds an important position in the oncology targeted therapy market, particularly demonstrating strong competitiveness in the later-line treatment of metastatic colorectal cancer. With the continuous rise in cancer incidence and the widespread adoption of precision medicine, the demand for anti-angiogenic therapies continues to grow, providing a stable market foundation for this drug. From a competitive landscape perspective, anti-angiogenic monoclonal antibodies such as Bevacizumab and small-molecule multi-target TKIs such as Regorafenib dominate the market. However, fruquintinib, with its high selectivity, favorable safety profile, and clear clinical benefits, has established differentiated advantages in later-line treatment settings. On the policy side, its inclusion in the national reimbursement drug list helps improve patient accessibility and promote market expansion, although volume-based procurement and healthcare cost-control policies continue to exert downward pressure on pricing. From a competitive standpoint, the emergence of various anti-angiogenic therapies and combination regimens with immunotherapy from both domestic and international players is intensifying market competition. Therefore, the future market performance of fruquintinib will depend on its progress in expanding indications (such as gastric cancer and lung cancer), developing combination strategies, and accumulating real-world evidence, as well as its overall competitive balance in terms of efficacy, safety, and cost.
This report is a detailed and comprehensive analysis for global Fruquintinib market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Fruquintinib market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Fruquintinib market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Fruquintinib market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Fruquintinib market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Fruquintinib
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Fruquintinib market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Hutchison China MediTech Limited, Takeda Pharmaceutical Company Limited, Sichuan Qingmu Pharmaceutical, Shanghai Boyi Chemical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Fruquintinib market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
1 mg capsule
5 mg capsule
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Application
Metastatic Colorectal Cancer (mCRC)
Inhibit Tumor Angiogenesis
Others
Major players covered
Hutchison China MediTech Limited
Takeda Pharmaceutical Company Limited
Sichuan Qingmu Pharmaceutical
Shanghai Boyi Chemical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Fruquintinib product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Fruquintinib, with price, sales quantity, revenue, and global market share of Fruquintinib from 2021 to 2026.
Chapter 3, the Fruquintinib competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Fruquintinib breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Fruquintinib market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Fruquintinib.
Chapter 14 and 15, to describe Fruquintinib sales channel, distributors, customers, research findings and conclusion.